UNASSIGNED: Abstract Objectives: Five randomized, phase 3 trials demonstrated the efficacy and safety of conjugated @entity172 / @entity178 (CE/BZA) in treating menopausal symptoms and preserving bone. This pooled analysis of these studies describes cardiovascular safety of CE/BZA. Methods: We pooled cardiovascular adjudicated safety data from healthy, nonhysterectomized, postmenopausal @entity1 who received >= 1 dose of CE 0.45 mg/BZA 20 mg (n=1585), CE 0.625 mg/BZA 20 mg (n=1583), any CE/BZA dose (n=4868), or placebo (n=1241) for up to 2 years in 5 trials. @entity1211 ( @entity1211 ), @entity301 ( @entity301 ), and cerebrovascular events were reviewed by 3 different independent adjudication committees and summarized using a meta-analytic approach. Results: Rate of @entity1211 per 1000 @entity1 -years (95% confidence interval [CI]) was 0.3 (0.0-2.0) in @entity1 taking CE 0.45 mg/BZA 20 mg, 0 (0.0-1.5) in those taking CE 0.625 mg/BZA 20 mg, 0.7 (0.0-1.5) among @entity1 taking any CE/BZA dose, and 0.6 (0.0-2.9) with placebo. Incidence of @entity64 per 1000 @entity1 -years (95% CI) was 0.4 (0.0-2.4), 0.2 (0.0-1.9), 0.44 (0.0-1.1), and 0.0 (0.0-1.7), respectively. @entity301 rate per 1000 @entity1 -years was 2.6 (0.0-5.6), 1.4 (0.0-3.9), and 2.0 (0.0-5.2). Compared with placebo, relative risk (95% CI) with any CE/BZA dose was 0.5 (0.1-1.8) for VTE, 0.5 (0.1-2.6) for @entity64 , and 0.63 (0.23-1.74) for @entity301 . Conclusions: Up to 2 years of CE 0.45 or 0.625 mg with BZA 20 mg had an acceptable cardiovascular safety profile, with rates of @entity64 and @entity301 comparable to placebo in healthy postmenopausal @entity1 . VTE risk was low.

Cardiovascular safety of conjugated @entity172 plus XXXX : meta-analysis of the SMART trials.

@entity172 :: ('MESH:D004967', 'Chemical') :: ['estrogens'] @entity178 :: ('MESH:C447119', 'Chemical') :: ['bazedoxifene'] @entity1 :: ('9606', 'Species') :: ['women', 'woman'] @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke'] @entity301 :: ('MESH:D003327', 'Disease') :: ['CHD', 'coronary heart disease'] @entity1211 :: ('MESH:D054556', 'Disease') :: ['Venous thromboembolic events', 'VTEs']
@entity178 :: (MESH:C447119,Chemical) :: ['bazedoxifene']
